LOS ANGELES, March 24, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. The presentation is scheduled for Thursday, March 27, 2014, at 9:00 am Eastern Time.
Additionally, Dr. Singh will be presenting on the following panels:
|12:00pm - 12:45pm: Autologous Immunotherapies|
|4:15pm - 4:45pm: Immunotherapies for Solid Tumors|
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.lionbio.com.
CONTACT: Investor Relations The Trout Group Gitanjali Jain Ogawa 646-378-2949 firstname.lastname@example.orgSource:Lion Biotechnologies, Inc.